Global Bone Morphogenetic Protein Growth Factor Therapy Market, By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP)-2, Recombinant Human Bone Morphogenetic Protein (rhBMP)-7), Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-Maxillofacial, Others) Industry Trends and Forecast to 2029.
Global Bone Morphogenetic Protein Growth Factor Therapy Market Analysis and Insights
Bone morphogenetic proteins (BMPs) are growth factors that encourage the formation of bone after a fracture. In addition, these proteins have a vital role during embryonic development in the formation of the skeleton. There are twenty variations of BMPs that have been discovered so far, out of which only two, BMP-2 and BMP-7, have been commercialized as bone graft substitutes for usage in specific orthopedic procedures.
- BMPs have an important role in bone and cartilage formation, and embryogenesis. Data Bridge Market Research analyses that the bone morphogenetic protein growth factor therapy market will grow at a CAGR of 4.9% during the forecast period of 2022 to 2029.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Recombinant Human Bone Morphogenetic Protein (rhBMP)-2, Recombinant Human Bone Morphogenetic Protein (rhBMP)-7), Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-Maxillofacial, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Medtronic (US), Stryker Corporation (US), Merck KGaA (Germany), Prospec-Tany Technogene Ltd. (Israel), Ember Therapeutics. (US), R&D Systems, Inc. (US), Thermo Fisher Scientific (US), Akron Biotechnology LLC (US), Sino Biological Inc. (China).
|
|
Market Opportunities
|
|
Bone Morphogenetic Protein Growth Factor Therapy Market Dynamics
Drivers
Major factors that are expected to boost the growth of the bone morphogenetic protein growth factor therapy market in the forecast are as follows:
-
The Rise in the Sports Regarding Injuries Around the World
Growing number of cases of sports injuries such as spinal injuries. The lumbar and cervical vertebrae of the spine are particularly vulnerable and require fusion which is one of the contributing factor for the market growth.
-
The Growing Incidence for Minimally Invasive Procedures
Increasing cases of spinal fusion incidences, small bone surgeries, and trauma upsurge the rise in the cases of minimally invasive procedures particularly in the low back pain and spinal disc dislocation.
-
The Technological Developments
Research and development is a key aspect of the company's growth strategy. Manufacturing businesses have conducted substantial study into the therapeutic potential of BMP in different orthopaedic conditions, such as osteoarthritis and soft tissue healing.
Additionally, the rising knowledge regarding the bone morphogenetic protein growth factor therapy is further estimated to cushion the growth of the bone morphogenetic protein growth factor therapy market.
Opportunities
In addition, the suitable reimbursement policies will further provide potential opportunities for the growth of the bone morphogenetic protein growth factor therapy market in the coming years.
Restraints/Challenges Global Bone Morphogenetic Protein Growth Factor Therapy Market
On the other hand, the increased expenses of the procedure is further projected to impede the growth of the bone morphogenetic protein growth factor therapy market in the timeline period. However, accessibility of substitute treatment might further challenge the growth of the bone morphogenetic protein growth factor therapy market in the near future.
This bone morphogenetic protein growth factor therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone morphogenetic protein growth factor therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The bone morphogenetic protein growth factor therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Bone Morphogenetic Protein Growth Factor Therapy Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market.
Recent Development
- In September 2019, Medtronic, an Irish medical device company, stated that pivotal, randomised, and prospective clinical trials for the use of Infuse bone graft have been approved by the FDA. The findings of the study could lead to the use of bone transplant in TLIF (Transforaminal Lumbar Interbody Fusion) spine operations.
Global Bone Morphogenetic Protein Growth Factor Therapy Market Scope
The bone morphogenetic protein growth factor therapy market is segmented on the basis of type and application. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Recombinant Human Bone Morphogenetic Protein (rhBMP)-2
- Recombinant Human Bone Morphogenetic Protein (rhBMP)-7
On the basis of type, the bone morphogenetic protein growth factor therapy market is segmented into recombinant human bone morphogenetic protein (rhBMP)-2 and recombinant human bone morphogenetic protein (rhBMP)-7.
Application
- Spinal Fusion
- Trauma
- Reconstructive Surgery
- Oral-Maxillofacial
- Others
On the basis of treatment, the bone morphogenetic protein growth factor therapy market is segmented into spinal fusion, trauma, reconstructive surgery, oral-maxillofacial and others.
Pipeline Analysis
The rhBMP-2 and rhBMP-7 are also used in the treatment of variety of bone related condition specially rsBMP-2 is extensively used in lumbar spinal fusion technique such as antierior and posterior survical fusion pipeline analysis of anticonvulsant drugs includes various pipeline therapies such as LP352, OPC-214870, Ganaxolone, CT-010, Vatiquinone E-2730, XEN496, and NBI 827104. Medtronic, Stryker, Merck KGaA, Prospec-Tany Technogene Ltd., Ember Therapeutics and others are the involved in the development of potential drugs for the development of cytokines and metabologens.
Bone Morphogenetic Protein Growth Factor Therapy Market Regional Analysis/Insights
The bone morphogenetic protein growth factor therapy market is analysed and market size insights and trends are provided by country, type and application as referenced above.
The countries covered in the bone morphogenetic protein growth factor therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the bone morphogenetic protein growth factor therapy market due to the rise in the adoption of advanced technology. Furthermore, the suitable reimbursement policies will further boost the growth of the bone morphogenetic protein growth factor therapy market in the region during the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Bone Morphogenetic Protein Growth Factor Therapy Market Share Analysis
The bone morphogenetic protein growth factor therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bone morphogenetic protein growth factor therapy market.
Some of the major players operating in the bone morphogenetic protein growth factor therapy market are:
- Medtronic (US)
- Stryker Corporation (US)
- Merck KGaA (Germany)
- Prospec-Tany Technogene Ltd. (Israel)
- Ember Therapeutics. (US)
- R&D Systems, Inc (US)
- Thermo Fisher Scientific (US)
- Akron Biotechnology LLC (US)
- Sino Biological Inc (China)
SKU-